Lv1
70 积分 2024-03-30 加入
Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis
7天前
已完结
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
26天前
已完结
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis
1个月前
已完结
中医对急性高山病的潜在治疗作用：发病机制、机制和未来方向
1个月前
已完结
Response to rozanolixizumab in patients with generalized myasthenia gravis (gMG) from the Phase 3 MycarinG study
1个月前
已关闭
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration
1个月前
已完结
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
1个月前
已完结
皖公网安备34019202002308
